China Biologic Products (CBPO +0.9) moves up on positive comments out of Aegis Capital this...
China Biologic Products (CBPO +0.9) moves up on positive comments out of Aegis Capital this morning. The firm raised its price target to $22 on the shares after China's National Development and Reform Commission announced a new round of retail price adjustments. The price ceilings for plasma-based products were raised, more notably, prices for various doses of human albumin would see an increase of over 5%. Human albumin represents 54.5% and 45.3% of China Biologic's 2011 and 9-month 2012 total revenue, respectively.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs